MXPA05007711A - Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino. - Google Patents

Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.

Info

Publication number
MXPA05007711A
MXPA05007711A MXPA05007711A MXPA05007711A MXPA05007711A MX PA05007711 A MXPA05007711 A MX PA05007711A MX PA05007711 A MXPA05007711 A MX PA05007711A MX PA05007711 A MXPA05007711 A MX PA05007711A MX PA05007711 A MXPA05007711 A MX PA05007711A
Authority
MX
Mexico
Prior art keywords
treatment
inflammatory bowel
bowel diseases
cop
copolymer
Prior art date
Application number
MXPA05007711A
Other languages
English (en)
Inventor
Basak Kayhan
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MXPA05007711A publication Critical patent/MXPA05007711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con el uso de copolimero 1 (acetato de glatiramer), un polipeptido relacionado con copolimero 1 o un peptido relacionado con copolimero 1, para el tratamiento de enfermedades inflamatorias del intestino tales como enfermedad de Crohn y colitis ulcerativa.
MXPA05007711A 2003-01-21 2004-01-20 Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino. MXPA05007711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44113603P 2003-01-21 2003-01-21
PCT/IL2004/000054 WO2004064717A2 (en) 2003-01-21 2004-01-20 Cop 1 for treatment of inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
MXPA05007711A true MXPA05007711A (es) 2005-09-30

Family

ID=32771907

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007711A MXPA05007711A (es) 2003-01-21 2004-01-20 Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.

Country Status (14)

Country Link
US (1) US8008258B2 (es)
EP (1) EP1592384B1 (es)
AU (1) AU2004206120B2 (es)
CA (1) CA2513567C (es)
DK (1) DK1592384T3 (es)
ES (1) ES2397836T3 (es)
MX (1) MXPA05007711A (es)
NO (1) NO333579B1 (es)
NZ (1) NZ569331A (es)
PT (1) PT1592384E (es)
RU (1) RU2339397C2 (es)
SI (1) SI1592384T1 (es)
WO (1) WO2004064717A2 (es)
ZA (1) ZA200505733B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CN1308683C (zh) * 2001-12-04 2007-04-04 特瓦制药工业有限公司 测量醋酸格拉默功效的方法
RU2410115C2 (ru) * 2004-05-07 2011-01-27 Пептиммьюн, Инк. Способы лечения заболеваний с помощью статистических сополимеров
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
CA2594022A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP2318012A4 (en) * 2008-07-25 2011-08-24 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES
LT2949335T (lt) 2009-08-20 2017-03-27 Yeda Research & Development Company, Ltd. Žemo dažnio glatiramero acetato terapija
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MY188328A (en) 2010-07-26 2021-11-30 Biologics Inc Qu Immunogenic anti-inflammatory compositions
BR112013008573A2 (pt) 2010-10-11 2016-07-12 Teva Pharma citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
EP2906719A4 (en) 2012-10-10 2016-11-09 Teva Pharma PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP6632607B2 (ja) 2014-05-02 2020-01-22 クー バイオロジックス インク．Ｑｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 抗微生物免疫修飾
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CA3062964A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
EP3624816A4 (en) 2017-05-15 2021-02-24 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH ADAPTIVE STEM CELLS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
IL140592A0 (en) * 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
PT2239269E (pt) 1998-09-25 2013-04-09 Yeda Res & Dev Uso de péptidos derivados de copolímero 1 como marcadores de peso molecular
AU6281599A (en) * 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en) * 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
WO2001095935A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
ATE329608T1 (de) * 2000-02-18 2006-07-15 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
AU2003204344A1 (en) * 2002-05-23 2003-12-11 Milder, Dan George Compositions and methods for the treatment of autoimmune diseases and neurological disorders
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases

Also Published As

Publication number Publication date
PT1592384E (pt) 2013-01-28
US8008258B2 (en) 2011-08-30
EP1592384A4 (en) 2008-12-31
EP1592384B1 (en) 2012-10-31
CA2513567C (en) 2012-10-23
NO20053860D0 (no) 2005-08-18
WO2004064717A3 (en) 2005-10-13
EP1592384A2 (en) 2005-11-09
NO333579B1 (no) 2013-07-15
CA2513567A1 (en) 2004-08-05
NZ569331A (en) 2010-08-27
RU2339397C2 (ru) 2008-11-27
US20060264354A1 (en) 2006-11-23
AU2004206120A1 (en) 2004-08-05
AU2004206120B2 (en) 2009-09-24
SI1592384T1 (sl) 2013-03-29
NO20053860L (no) 2005-10-20
WO2004064717A2 (en) 2004-08-05
ES2397836T3 (es) 2013-03-11
ZA200505733B (en) 2006-10-25
RU2005126412A (ru) 2006-01-27
DK1592384T3 (da) 2012-12-17

Similar Documents

Publication Publication Date Title
MXPA05007711A (es) Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.
IL158088A (en) Use of an antibody linked to ailim for the preparation of a pharmacological preparation for suppressing or preventing inflammatory bowel disease
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2007048857A8 (es) USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
EP1129106A4 (en) CYCLIC CONOTOXIN PEPTIDES
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
MXPA05008080A (es) Inhibidores peptidicos de toxinas derivadas de la ll-37.
WO2006082581A3 (en) Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
JP2004511492A5 (es)
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
MX2009004196A (es) Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes.
CY1113827T1 (el) Cop 1 για την αγωγη των φλεγμονωδων παθησεων του εντερου
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
EP2025754A3 (en) Moraxella (Branhamella) catarrhalis antigens
WO2004000870A3 (en) Two synthetic peptides for treatment and prevention of cancers
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
GB0228441D0 (en) Splice variant
ATE417061T1 (de) Scorpionpeptid als blutdrucksenkendes mittel
YU70903A (sh) Novi peptid ligandi za integrine leukocita

Legal Events

Date Code Title Description
FG Grant or registration